Early use of steroids affects immune cells and impairs immunotherapy efficacy

Treatment of patients with non-small cell lung cancer (NSCLC) has been completely redesigned in the last years with the introduction of immune checkpoint blockade (ICB). Antiprogrammed cell death 1 (PD-1) or programmed death-ligand 1 (PD-L1) drugs are currently indicated worldwide for treatment of NSCLC.1 Known predictive positive biomarkers of response to these agents are PD-L1 expression and tumour mutational burden in tumour samples, but being the overall response rate is only 20%2 the identification of biomarker of resistance is desperately needed.

Abstract licence: CC BY-NC-ND

1. 1.

   Single-Cell RNA Sequencing Reveals T Helper Cells Synthesizing Steroids De Novo to Contribute to Immune Homeostasis · 2014

2. 6.

   Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer · 2018

10 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.